Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 360° synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing prevalence of obesity-related conditions
3.2.1.2 Government regulations and guidelines
3.2.1.3 Increase in technological advancements
3.2.2 Industry pitfalls & challenges
3.2.2.1 Side effects and adverse reactions
3.2.2.2 High cost of anti-obesity drugs
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Technological landscape
3.5.1 Core technologies
3.5.2 Adjacent technologies
3.6 Porter’s analysis
3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Product, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Prescription drugs
5.3 OTC drugs
Chapter 6 Market Estimates and Forecast, By Action Pathway, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Peripherally acting drugs
6.3 Centrally acting drugs
Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Hospital pharmacies
7.3 Retail pharmacies
7.4 Drug stores
7.5 E-commerce
Chapter 8 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 North America
8.2.1 U.S.
8.2.2 Canada
8.3 Europe
8.3.1 Germany
8.3.2 UK
8.3.3 France
8.3.4 Spain
8.3.5 Italy
8.3.6 Netherlands
8.3.7 Rest of Europe
8.4 Asia Pacific
8.4.1 China
8.4.2 Japan
8.4.3 India
8.4.4 Australia
8.4.5 South Korea
8.4.6 Rest of Asia Pacific
8.5 Latin America
8.5.1 Brazil
8.5.2 Mexico
8.5.3 Argentina
8.5.4 Rest of Latin America
8.6 Middle East and Africa
8.6.1 South Africa
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Rest of Middle East and Africa
Chapter 9 Company Profiles
9.1 Arena Pharmaceuticals, Inc.
9.2 AstraZeneca PLC
9.3 Boehringer Ingelheim International GmbH
9.4 Currax Pharmaceuticals LLC
9.5 Eli Lily & Co
9.6 F. Hoffmann-La Roche Ltd.
9.7 Gelesis
9.8 GlaxoSmithKline plc
9.9 Merck & Co., Inc.
9.10 Novartis AG
9.11 Novo Nordisk A/S
9.12 Orexigen Therapeutics, Inc.
9.13 Pfizer Inc.
9.14 Rhythm Pharmaceuticals, Inc.
9.15 Vivus, Inc.
